Generic Oncology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Generic Oncology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


The global Generic Oncology Drugs Market has experienced remarkable growth, with revenues reaching approximately US$ 24.8 billion in 2024. It is expected to surge to a valuation of US$ 48 billion by the end of 2031, as highlighted in a recent study conducted by Fairfield Market Research.

Key Market Drivers

Affordable Generic Oncology Treatments and FDA Approvals

The oncology drug market is often characterized by high costs, limiting accessibility for the general public. The expenses associated with cancer treatment pose challenges for patients. Generic oncology drugs address this issue by offering cost-effective alternatives that are nearly 80% less expensive than branded cancer medications.

For example, Pemetrexed (500 mg), a chemotherapy injection for lung cancer treatment, is now available at Rs 2,800 instead of Rs 22,000. The affordability of generic oncology drugs enhances the likelihood of patients receiving better care by reducing treatment costs.

Numerous governments are actively promoting the use of generic medications to reduce healthcare expenses. Research and development (R&D) efforts are ongoing, leading to the release of numerous new generic drugs.

Growing Public Awareness and Preventive Measures

The market is also expanding due to increased public awareness of the benefits of early cancer detection and a growing inclination toward preventive measures. These factors contribute to the rising demand for generic oncology drugs.

For instance, Alembic Pharma received final FDA approval for its generic version of Paclitaxel injection, used in cancer treatment, in October 2022, further driving market growth.

Challenges Impacting Market Growth

Stringent Regulatory Requirements

The approval process for generic pharmaceuticals involves rigorous scrutiny by the FDA to ensure accuracy, assess side effects, and verify the substances used. Failure to meet regulatory requirements can result in the recall of pharmaceuticals. The strict regulatory environment hinders market expansion.

Uncertainty Surrounding Efficacy

Uncertainty about the effectiveness of generic cancer treatments, a lengthy approval process, and the increasing use of alternative cancer drugs are challenges limiting market growth.

Country-Wise Insights

U.S.: Rising Cancer Incidences

The U.S. market is expected to account for approximately 88.9% of the North American generic oncology drugs market share in 2023. The country has witnessed a significant increase in annual cancer incidences, making it a highly profitable market for generic oncology drugs.

Favorable government initiatives and policies are further enhancing the capacity of manufacturers. These factors create a conducive environment for American suppliers of generic cancer medicines.

India: Emerging Supplier

The Indian pharmaceutical and healthcare sectors are growing rapidly, with domestic manufacturers introducing new medicines at remarkably low prices. Factors such as abundant labor availability, low manufacturing costs, and government support are attracting generic cancer drug manufacturers to establish operations in India.

The commercial potential of generic oncology treatments in India is bolstered by low production costs, supportive government policies, easy access to raw materials, and cost-effective research and development.

Competitive Landscape

Mergers and acquisitions have been prominent growth strategies in the global industry. Several well-known companies are diversifying their product portfolios through acquisitions and expanding into both existing and emerging markets.

Key Players Profiled
• Novartis
• Pfizer
• GSK
• Celgene
• Teva Pharmaceuticals
• Merck & Company
• Aurobindo Pharma
• Hikma Pharmaceuticals
• Mylan
• Gland Pharma
• NATCO Pharma

Key Segments Covered in Generic Oncology Drugs Industry Research

Molecule:
• Large Molecule
• Small Molecule

Route of Administration:
• Oral
• Parenteral

Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Managed Care Institutions

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Generic Oncology Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Generic Oncology Drugs Market Outlook, 2018 – 2031
3.1. Global Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Large Molecule
3.1.1.2. Small Molecule
3.2. Global Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Oral
3.2.1.2. Parenteral
3.3. Global Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacy
3.3.1.2. Retail Pharmacy
3.3.1.3. Online Pharmacies
3.3.1.4. Managed Care Institutions
3.4. Global Generic Oncology Drugs Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Generic Oncology Drugs Market Outlook, 2018 – 2031
4.1. North America Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Large Molecule
4.1.1.2. Small Molecule
4.2. North America Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Oral
4.2.1.2. Parenteral
4.3. North America Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacy
4.3.1.2. Retail Pharmacy
4.3.1.3. Online Pharmacies
4.3.1.4. Managed Care Institutions
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
4.4.1.2. U.S. Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
4.4.1.3. U.S. Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.4.1.4. Canada Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
4.4.1.5. Canada Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
4.4.1.6. Canada Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Generic Oncology Drugs Market Outlook, 2018 – 2031
5.1. Europe Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Large Molecule
5.1.1.2. Small Molecule
5.2. Europe Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Oral
5.2.1.2. Parenteral
5.3. Europe Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacy
5.3.1.2. Retail Pharmacy
5.3.1.3. Online Pharmacies
5.3.1.4. Managed Care Institutions
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Germany Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
5.4.1.2. Germany Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.3. Germany Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.4. U.K. Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
5.4.1.5. U.K. Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.6. U.K. Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.7. France Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
5.4.1.8. France Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.9. France Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.10. Italy Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
5.4.1.11. Italy Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.12. Italy Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.13. Turkey Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
5.4.1.14. Turkey Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.15. Turkey Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.16. Russia Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
5.4.1.17. Russia Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.18. Russia Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.1.19. Rest of Europe Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
5.4.1.20. Rest of Europe Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
5.4.1.21. Rest of Europe Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Generic Oncology Drugs Market Outlook, 2018 – 2031
6.1. Asia Pacific Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Large Molecule
6.1.1.2. Small Molecule
6.2. Asia Pacific Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Oral
6.2.1.2. Parenteral
6.3. Asia Pacific Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacy
6.3.1.2. Retail Pharmacy
6.3.1.3. Online Pharmacies
6.3.1.4. Managed Care Institutions
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. China Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
6.4.1.2. China Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.3. China Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.4. Japan Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
6.4.1.5. Japan Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.6. Japan Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.7. South Korea Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
6.4.1.8. South Korea Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.9. South Korea Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.10. India Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
6.4.1.11. India Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.12. India Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.13. Southeast Asia Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
6.4.1.14. Southeast Asia Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.15. Southeast Asia Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.1.16. Rest of Asia Pacific Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
6.4.1.17. Rest of Asia Pacific Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
6.4.1.18. Rest of Asia Pacific Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Generic Oncology Drugs Market Outlook, 2018 – 2031
7.1. Latin America Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Large Molecule
7.1.1.2. Small Molecule
7.2. Latin America Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
7.2.1.1. Oral
7.2.1.2. Parenteral
7.3. Latin America Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacy
7.3.1.2. Retail Pharmacy
7.3.1.3. Online Pharmacies
7.3.1.4. Managed Care Institutions
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
7.4.1.2. Brazil Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.3. Brazil Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.4. Mexico Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
7.4.1.5. Mexico Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.6. Mexico Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.7. Argentina Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
7.4.1.8. Argentina Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.9. Argentina Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.1.10. Rest of Latin America Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
7.4.1.11. Rest of Latin America Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
7.4.1.12. Rest of Latin America Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Generic Oncology Drugs Market Outlook, 2018 – 2031
8.1. Middle East & Africa Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Large Molecule
8.1.1.2. Small Molecule
8.2. Middle East & Africa Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Oral
8.2.1.2. Parenteral
8.3. Middle East & Africa Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacy
8.3.1.2. Retail Pharmacy
8.3.1.3. Online Pharmacies
8.3.1.4. Managed Care Institutions
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. GCC Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
8.4.1.2. GCC Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.3. GCC Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.4. South Africa Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
8.4.1.5. South Africa Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.6. South Africa Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.7. Egypt Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
8.4.1.8. Egypt Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.9. Egypt Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.10. Nigeria Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
8.4.1.11. Nigeria Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.12. Nigeria Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.1.13. Rest of Middle East & Africa Generic Oncology Drugs Market by Molecule, Value (US$ Bn), 2018 – 2031
8.4.1.14. Rest of Middle East & Africa Generic Oncology Drugs Market by Route of Administration, Value (US$ Bn), 2018 – 2031
8.4.1.15. Rest of Middle East & Africa Generic Oncology Drugs Market by Distribution Channel, Value (US$ Bn), 2018 – 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by Route of Administration Heat map
9.2. Manufacturer vs by Route of Administration Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Novartis
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Pfizer
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. GSK
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Celgene
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Teva Pharmaceuticals
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Merck & Company
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Aurobindo Pharma
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Hikma Pharmaceuticals
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Mylan
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Gland Pharma
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. NATCO Pharma
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings